All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
MITHIC-FL1: Mosunetuzumab monotherapy in newly diagnosed follicular lymphoma
|
Chemoimmunotherapy remains the standard 1L therapy for FL but is associated with limitations, including early progression and complications such as infections and secondary cancers.1 The MITHIC-FL1 trial aims to explore a chemotherapy-free treatment option, challenging traditional 1L chemoimmunotherapy.1 MITHIC-FL1 is a phase II trial evaluating the efficacy and safety of fixed-duration SC mosunetuzumab, a CD20xCD3 bispecific antibody, monotherapy in patients with ND FL (dosed, n = 78; response evaluable, n = 76).1 Primary analysis results from this trial were presented at the 66th ASH Annual Meeting and Exposition by Falchi.1 The primary endpoint was CR rate per Lugano response criteria.1 |
| Key learnings |
| With a median follow-up of 13.3 months and a median treatment duration of 4.8 months, 86% of patients experienced a reduction in tumor burden of ≥80% from baseline. |
| The ORR was 96%, with a CR rate of 80%. The 1-year PFS and OS rates were 91% and 98.7%, respectively. CR was maintained at 1 year in 90% of patients who achieved a CR. |
| Most TEAEs and CRS events were mild and manageable. Low grade injection site reactions (70%), infections (56%), and CRS events (54%) were the most common TEAEs, with the majority being Grade I events. |
| Overall, efficacy and safety data from the MITHIC-FL1 study suggest that mosunetuzumab monotherapy could be a viable treatment option for patients with ND FL and warrant further investigation of SC mosunetuzumab in comparative 1L FL trials. |
Abbreviations: 1L, first-line; ASH, American Society of Hematology; CRS, cytokine release syndrome; CR, complete response; FL, follicular lymphoma; ND, newly diagnosed; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; SC, subcutaneous; TEAE, treatment-emergent adverse event.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
What is your preferred therapy class when planning treatment for a patient with R/R DLBCL after 2 or more lines of systemic therapy ?
